Carcinoma cell specific marker MIG7 from MyBioSource.com

Identification of genes that are specifically expressed in a cancer cell-specific manner can be useful for detection and diagnosis of disease progression. One of such marker is a receptor tyrosine kinase ligands in concert with ligation of alphavbeta5 integrin induce expression of MIG7 restricted to carcinoma cells. MIG7 expression in occult tumor cells made it a marker gene for detection of such tumors. The MIG7 expression in the lymph nodes of endometrial carcinoma xenograft mice was present in 78% compared to negative controls (1). The MIG7 expression was evident in 87% of breast, lung, colon and ovary cancer specimens compared to normal tissues. Hepatocyte growth factor (HGF), a cytokine involved in tumorigenesis and most metastases, initiates cell migration by binding to the protooncogene c-Met receptor. In epithelial carcinoma cells, c-Met activation causes the breakdown of E-cadherin cell-cell contacts leading to cell spreading. While The breakdown of E-cadherin contacts is immediate, HGF-induced migration requires de novo transcription and induction of MIG7 (2), suggesting MIG7 as an early marker for migrating and circulating carcinoma cells. The blocking antibodies to alphavbeta5 integrin inhibited HGF induction of Mig-7 in RL95 cells and MIG7-specific antisense oligonucleotides inhibited scattering of endometrial carcinoma cell line RL95in vitro (2). The MIG7 factor is more specific than MET factor, a receptor tyrosine kinase that binds scatter factor and is a marker of poor progression, in endometrial carcinoma as compared to endometrial tissue samples. MIG7 is a 207 amino acid protein with an apparent molecular weight of 25kDa. MIG7 is a cancer cell- and cytotrophoblast-specific; spelenocysteine and has a selenium binding motif. MIG7 is a membrane binding protein with single transmembrane domain spanning amino acids 35-57 with extracytoplasmic amino terminal end. The MIG7 gene was mapped to chromosome 2p21-p22. The MIG7-selective antibodies were generated against an amino terminal peptides. MyBioSource has generated epitope specific rabbit anti- ESPE4 polyclonal (epitope-specific) antibodies utilizing linear and cyclic peptide sequences. The ESPE4 antibodies are affinity purified over immobilized antigen based chromatography, and the purified immunoglobulin are stabilized in antibody stabilization buffer. Limited quantities of the antigenic blocking peptide for ESPE4 antibodies are also available (inquire for availability)